Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, Rebekah Pennington, Barry Hounsome, Ellen Lever, Andrew Metry, Edith Poku, Yit Yang, Simon P Harding, Andrew Lotery, Usha Chakravarthy, John Brazier
BACKGROUND: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis® ; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea® ; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin® ; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula oedema due to central retinal vein occlusion, but their relative clinical effectiveness, cost-effectiveness and impact on the UK NHS and Personal Social Services have never been directly compared over the typical disease treatment period...
June 2021: Health Technology Assessment: HTA